Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 2548 results for methods

  1. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued Reference number: GID-TAG375

    Technology appraisal guidance
    Discontinued

  2. Microthane implants for breast reconstruction or breast augmentation (discontinued)

    Discontinued Reference number: GID-MT267

    Medical technologies guidance
    Discontinued

  3. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  4. Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

    In development Reference number: GID-TA11745 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued Reference number: GID-TA11176

    Technology appraisal guidance
    Discontinued

  6. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued Reference number: GID-TA11178

    Technology appraisal guidance
    Discontinued

  7. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development Reference number: GID-TA10800 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  9. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  10. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued Reference number: GID-TAG413

    Technology appraisal guidance
    Discontinued

  11. Selumetinib for treating differentiated thyroid cancer [ID1079]

    Discontinued Reference number: GID-TA10207

    Technology appraisal guidance
    Discontinued

  12. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued Reference number: GID-TA10522

    Technology appraisal guidance
    Discontinued

  13. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued Reference number: GID-TA11177

    Technology appraisal guidance
    Discontinued

  14. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued Reference number: GID-TA11181

    Technology appraisal guidance
    Discontinued

  15. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued